Hims & Hers 10-Q puts a $60 million number on the FTC case

Hims & Hers Health put a dollar figure on its federal legal exposure this week. In the Form 10-Q it filed August 10 for the second quarter of 2026, the company said that "As of June 30, 2026, the Company had recorded a legal contingency accrual of approximately $60 million for this matter in accordance with ASC 450, Contingencies" — "this matter" being the Federal Trade Commission case filed against it on July 29 ^[1].

The same filing shows total accrued legal contingencies of $62.5 million, compared with $0 at the end of 2025 ^[1]. The company had disclosed a $15 million probable-loss accrual in its May filing, according to CNBC reporting cited in coverage of the case ^[1][2]. Sources describe the quarter's charge slightly differently: one account says the accrual for the FTC matter reached roughly $60 million by June 30 ^[1], while another reports a $47.5 million legal contingency charge booked in the second quarter, bringing the year-to-date total to $62.5 million ^[2]. The 10-Q also warns the number "may decrease or increase materially in future periods" ^[1].

What the case is about

The FTC, joined by the Utah Division of Consumer Protection and the People of the State of California, filed a 48-page, nine-count complaint in the Northern District of California ^[1]. It alleges Hims ran tracking code from at least 15 advertising platforms — including Meta, Snap, TikTok, Google and Pinterest — that reported what visitors did on the way to a prescription for erectile dysfunction, hair loss, "a weight-loss shot, or an antidepressant," while the site marketed a "100% online, private, and secure process" ^[1]. Three of the nine counts have nothing to do with data. Those claims, brought under the Restore Online Shoppers' Confidence Act, allege the company charged people before they ever spoke with a provider and buried the cancel option several clicks inside an "add/remove items from order" menu ^[1][2]. The complaint says key auto-renewal disclosures appeared in "small, low-contrast text" ^[2].

The 10-Q confirms the FTC issued a civil investigative demand in October 2023, and says the company "engaged in good faith settlement negotiations with the FTC, but these negotiations were unsuccessful" ^[1]. It also discloses a follow-on consumer class action, Doe v. Hims & Hers Health, Inc., filed in the same court under the federal wiretap statute and two California privacy laws ^[1]. A separate securities class action followed, with a class period stretching back to August 2025 ^[2].

Hims disputes the allegations, calling the suit "baseless" and "an effort to generate headlines at our expense," and says it will "vigorously defend" ^[1][2]. CEO Andrew Dudum told CNBC on August 18 that the agency "wanted more of a headline than a real agreement here" ^[1].

Why it matters for patients

For people who bought GLP-1 medications or other prescriptions through a telehealth site, the practical issue is what left the browser during signup. The complaint describes two mechanisms: uploading customer lists directly to ad platforms, and embedding pixels that report events such as page viewed, form answered, item added to cart and purchase completed ^[1]. The date range for that conduct is redacted in the public complaint, so it is not publicly known when it started or whether it stopped ^[1].

This is not unique to one company. A 2022 audit by STAT News and The Markup of 50 direct-to-consumer telehealth sites found 25 reported cart adds or checkouts to at least one big tech platform, 13 captured answers to medical intake questions, and 35 sent names, emails or phone numbers ^[1]. At least 12 advertised themselves as HIPAA-compliant ^[1]. HIPAA generally covers the affiliated provider group, not the marketing website where the checkout page and the pixels sit ^[1].

The billing claims also matter for anyone on a recurring plan. If the FTC prevails, remedies sought include a permanent injunction, disgorgement, and civil penalties of up to $2,500 per violation under California statutes — an order that could force changes to how the company enrolls, bills and cancels subscribers ^[1][2].

What happens next

No trial date appears in the sources. Hims reported $753 million in second-quarter revenue, 2.9 million subscribers and $92 in monthly revenue per subscriber, with gross margin down from 76% to 64% as it shifted from compounded GLP-1s to branded products through its Novo Nordisk partnership ^[1][2]. Whether the accrual holds at $60 million is, by the company's own language, unsettled ^[1].